| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 7 | +85.71% | +0.03% | +0.10% | -0.08% | -6.68% | — |
| 14d | 7 | +100.00% | -1.77% | +0.33% | -2.10% | -10.13% | — |
| 30d | 7 | +71.43% | -4.26% | -0.74% | -3.52% | -14.01% | — |
| 60d | 7 | +100.00% | -20.61% | +3.46% | -24.07% | -23.03% | — |
| 90d | 7 | +100.00% | -10.93% | +4.28% | -15.21% | -38.04% | — |
| 180d | 7 | +100.00% | -41.92% | +4.09% | -46.01% | -65.63% | — |
| 1y | 7 | +100.00% | -69.45% | +2.59% | -72.04% | -67.94% | — |
| 2y | 7 | +85.71% | -85.83% | +4.17% | -90.00% | -89.76% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED |
|---|---|---|---|---|---|---|---|
| PRLD PRELUDE THERAPEUTICS INC | PURCHASE EVP and Chief of Business Oper | 17,000 | $12.85 | $218.4K | 20,750 | Sep 2, 2021 | Sep 7, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 6,727 | $41.52 | $279.3K | 10,680 | Sep 2, 2021 | Sep 7, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 17,000 | — | — | 207,796 | Sep 2, 2021 | Sep 7, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 3,343 | $40.29 | $134.7K | 17,407 | Sep 2, 2021 | Sep 7, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 6,930 | $42.50 | $294.5K | 3,750 | Sep 2, 2021 | Sep 7, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | PURCHASEGRANT Stock grant | 85,000 | — | — | 85,000 | Jul 20, 2021 | Jul 22, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 3,295 | — | — | 4,323 | Apr 29, 2021 | Apr 30, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | PURCHASE EVP and Chief of Business Oper | 3,295 | $1.89 | $6.2K | 7,045 | Apr 29, 2021 | Apr 30, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 3,295 | $40.29 | $132.8K | 3,750 | Apr 29, 2021 | Apr 30, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 200 | $40.00 | $8.0K | 3,750 | Apr 8, 2021 | Apr 15, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | PURCHASEGRANT Stock grant | 200 | $1.89 | $378 | 3,950 | Apr 8, 2021 | Apr 15, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 200 | — | — | 7,618 | Apr 8, 2021 | Apr 15, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | PURCHASEGRANT Stock grant | 828 | $1.89 | $1.6K | 4,578 | Apr 7, 2021 | Apr 9, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 828 | $40.08 | $33.2K | 3,750 | Apr 7, 2021 | Apr 9, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | SALE EVP and Chief of Business Oper | 828 | — | — | 7,818 | Apr 7, 2021 | Apr 9, 2021 ↗ |
| PRLD PRELUDE THERAPEUTICS INC | PURCHASE EVP and Chief of Business Oper | 3,750 | $19.00 | $71.3K | 3,750 | Sep 29, 2020 | Sep 29, 2020 ↗ |